Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilysys Inc (AGYS) vs Smith & Nephew plc (SNN) Price & Performance

Agilysys IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Agilysys Inc vs Smith & Nephew plc — how do they compare? Agilysys Inc trades at $107.52 (market cap $3.00B), while Smith & Nephew plc trades at $30.23 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 4.2× Agilysys Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.

AGYSSNN
Market Cap
$3.00B$12.54B
Sector
TechnologyHealth
52-Week High
$141.12$38.70
52-Week Low
$62.19$28.73
Enterprise Value
$2.90B$15.57B
Dividend Yield
2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agilysys Inc

Agilysys (AGYS) trades at $107.35, up 0.35% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q1 and Q2 2026 earnings beats, record subscription revenue growth, and improved FY27 guidance. Technical indicators suggest bullish momentum with support at $106 and resistance at $108. The company's hospitality software solutions are gaining traction through partnerships and AI-driven innovation.

Outlook remains positive with 100% analyst buy ratings and $118.33 consensus price target representing 10.2% upside. Key opportunities include subscription revenue growth and Marriott deployment progress, while risks include execution challenges and competitive pressures in the hospitality technology sector.

Smith & Nephew plc

SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.

The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.

Returns comparison

Trailing returns across standard periods

About Agilysys Inc

Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.

Read more on AGYS

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN